LNTH - Lantheus to sell RELISTOR's royalty rights intensifies focus on radiopharmaceutical business
2023-08-03 08:13:29 ET
- Lantheus Holdings ( NASDAQ: LNTH ) announced a divestiture of the sales-based royalty rights of its opioid antagonist RELISTOR.
- The company said the sale of this non-core asset allows it to focus on the core radiopharmaceutical business.
- HealthCare Royalty has acquired the royalty rights on worldwide net sales of RELISTOR, while Lantheus retains the rights to future sales-based milestone payments.
- Under terms, Lantheus received an initial payment of about $98 million and has the right to receive an additional payment of $5 million if worldwide net sales of RELISTOR in 2025 exceed a specified threshold.
- LNTH -9.6% premarket to $74.0
- Source: Press Release
For further details see:
Lantheus to sell RELISTOR's royalty rights, intensifies focus on radiopharmaceutical business